Key Takeaways

  • Applied Nutrition upgraded FY26 Revenue guidance to approximately £148 million, ahead of the previous £140.3 million analyst consensus.
  • The company agreed to acquire Nutrablend Group, a Buffalo, New York manufacturer, for $16 million, adding US production capacity for the first time.
  • A licensing agreement with Mondelez International will put branded sports-nutrition products into 2,200 Walmart stores and 1,300 GNC locations from August 2026.
  • H1 FY26 revenue rose 56.5% to £74.5 million, with adjusted EBITDA up 55.8% to £21.5 million and net cash of £26.4 million.
  • Long-standing Shareholder JD Sports Fashion sold its entire remaining 9.1% stake in April 2026, widening the free float.

Applied Nutrition plc (LSE:APN), the Liverpool-headquartered maker of protein powders, pre-workout supplements and diet gummies, has told investors it now expects to beat its own full-year revenue guidance, while agreeing to buy a Manufacturing Facility in upstate New York. The announcement, made on 1 June 2026, bundled a trading upgrade with an Acquisition and a new US retail licensing agreement.

For a Business that only listed on the London Stock Exchange 's Main Market in October 2024, the update is a significant marker of intent: Applied Nutrition is no longer content to export from the UK into the US market, but wants to manufacture there too.

What Happened

In a joint trading update, acquisition announcement and collaboration statement, Applied Nutrition (LSE:APN) said it now expects FY26 revenue (for the year ending 31 July 2026) of approximately £148 million, ahead of the £140.3 million analyst consensus it had previously been guiding towards, with EBITDA Margin in line with the 28.2% consensus estimate. Those figures exclude any contribution from the acquisition announced the same day.

The company agreed to buy Nutrablend Group, a US sports-nutrition manufacturer based in Buffalo, New York, for $16 million (around £12 million), funded from existing cash resources. The deal brings a freehold 107,000 sq ft facility, five powder-filling lines, three stick-pack machines, roughly $5 million of inventory, around 100 staff, and two existing brands, Basic Supplements and GR8 Lifestyle.

Alongside this, Applied Nutrition announced a licensing agreement with Mondelēz International to develop "AN Supps & SOUR PATCH KIDS" and "AN Supps & SWEDISH FISH" branded sports-nutrition products for the US and Canadian markets, launching in August 2026 across 2,200 Walmart stores and 1,300 GNC corporate locations.

Why It Matters

North America has long been positioned as the company's biggest growth opportunity, but until now Applied Nutrition manufactured almost everything in the UK and shipped it across the Atlantic. Owning US production capacity should cut logistics costs, shorten delivery times and reduce the currency and freight risk built into a transatlantic Supply chain. Management estimates the Buffalo site alone could support production capacity equivalent to around $300 million of annual revenue.

The Mondelēz collaboration is equally significant: it gives Applied Nutrition instant, large-scale shelf presence with two of America's biggest retailers, using globally recognised confectionery brands to help a relatively unknown UK label cut through in a crowded market.

Latest Financial and Operational Performance

The acquisition and Mondelēz news followed a strong first half. In interim results published on 23 March 2026, Applied Nutrition reported H1 FY26 revenue of £74.5 million, up 56.5% on £47.6 million in H1 FY25. Adjusted EBITDA rose 55.8% to £21.5 million, with margin broadly stable at 28.9% versus 29.0% a year earlier. Statutory profit before tax climbed 77.1% to £20.9 million, and net cash stood at £26.4 million, up from £10.9 million.

Growth was broad-based: UK revenue rose 45.8% to £31.5 million, Europe grew 37.5% to £8.8 million, and the "international" category, which includes the US, grew 74.5% to £34.2 million, with Latin American sales up 110%. Management described US operations as still "early-stage."

That built on a full FY25 in which revenue rose 24.2% to £107.1 million and adjusted EBITDA rose 18.8% to £30.9 million, with free Cash Flow conversion improving sharply to 72.4% from 35.3%.

In April 2026, JD Sports Fashion plc, a long-standing shareholder, sold its entire remaining 9.1% stake, 22.75 million shares, at £2.15 each, raising around £49 million. Applied Nutrition received no proceeds, but the clean exit removed an overhang and widened the free float. The company does not expect to pay a Dividend before FY27, preferring to retain cash for capacity Investment and further acquisitions.

Key Numbers

  • FY26 revenue guidance upgraded to approximately £148 million (previous consensus: £140.3 million)
  • H1 FY26 revenue: £74.5 million, up 56.5% year-on-year
  • H1 FY26 adjusted EBITDA: £21.5 million, margin 28.9%
  • H1 FY26 net cash: £26.4 million
  • FY25 revenue: £107.1 million, up 24.2%; adjusted EBITDA £30.9 million
  • Nutrablend acquisition price: $16 million (approximately £12 million)
  • Nutrablend facility: 107,000 sq ft in Buffalo, New York; approximately 100 employees
  • JD Sports Fashion plc sold its full 9.1% stake (22.75 million shares) at £2.15 for c.£49 million, April 2026

Growth Opportunities

Beyond Nutrablend, Applied Nutrition has been expanding UK manufacturing too: FY25 results referenced a factory extension raising domestic capability to around £200 million of revenue, with a further "phase 3" extension under construction expected to lift that to £300 million, alongside a new distribution centre and head office. The company is also diversifying beyond core sports nutrition, including a food-licensing tie-up with Morrisons announced in December 2025 and expansion into Latin America, Asia and Eastern Europe.

Risks Investors Should Know

Fast growth brings integration risk: Nutrablend is Applied Nutrition's first acquisition since listing, and folding a US facility and workforce into the group carries risk organic growth does not. The supplements category is intensely competitive in the US, where Brand recognition still lags UK rivals. Much recent growth has come from newer, smaller markets, which can be lumpier than established regions. With no dividend expected before FY27, returns rest on continued execution rather than income.

What to Watch Next

Investors should watch for confirmation of the Nutrablend completion timetable, early trading data from the August 2026 Walmart and GNC launches, and the FY26 full-year results, expected in the autumn, confirming whether the upgraded £148 million revenue guidance and 28.2% margin target were met. Progress on the UK "phase 3" factory extension and new distribution centre will also show how management is balancing UK and US investment.

Outlook

Applied Nutrition has moved decisively to back its stated ambition of building a genuine US manufacturing and retail presence, doing so from financial strength rather than necessity. The upgraded guidance suggests underlying trading remains robust, while the Nutrablend deal and Mondelēz agreement give the North American strategy tangible substance. The near-term test will be integration and execution rather than intent.